List view / Grid view
The TAp63 tumour suppressor protein, two micro RNAs (miRNAs) and the AURKA gene can all suppress cutaneous squamous cell carcinoma (cuSCC) development, find researchers.
Development of cell line expression systems to produce biologic medicines is complex, multi-stage and time consuming, requiring specific expertise and access to suitable technologies. This can limit the development of novel medicines to existing users and may restrict companies developing new medicines. In this article, major methods and technologies used…
A study has demonstrated the success of a 2D printing method to create cell arrays that reflect the body's natural environment, allowing researchers to study stem cell differentiation.
Drug Target Review explores the findings of a recent review of molecular, cellular, multi-cellular and tissue engineering and modelling technologies for drug design.
Many cell lines require the addition of specific growth factors to their culture media even if the media contains serum.
A new imaging technique, which has revealed 3D forces exerted by tiny cell clusters, could help scientists understand how tissue forms, how wounds heal or how tumours spread.
Flexible and intuitive operation of a wide range of biological processes with the SciVario® twin bioreactor control system.
More effective drugs could be developed due to a new technique that has allowed scientists to decipher how millions of individual cells are communicating with each other on miniature tumours grown in a lab.
A key modifier has been identified by researchers in a large fruit fly genetic deletion related to neurodevelopmental disorders such as schizophrenia and autism.
Research has shown that leaky gut, the break down of gut lining junctions, could be targeted to reduce inflammation using metformin using an organoid model.
Researchers have provided new insight into the role of cyclic AMP (cAMP) in regulating the immune response which may lead to new ways of treating diseases.
Scientists have found that a molecule present in our blood, called C4BP (β-), could be used in a therapeutic capacity for lupus as well as potentially other autoimmune disorders.
An innovation using artificial intelligence to analyse developing lung cell developments in vitro revealed what promotes them to develop and allowed researchers to create better quality lung tissue models.
Research has identified that putrescine, which aids macrophages in clearing dead cells, is lacking in atherosclerosis animal models and could be a potential therapeutic for the condition.
Researchers have developed a new body-on-chip technology that can demonstrate the pharmacokinetics and pharmacodynamics of drugs in a pre-clinical setting without the need for animal testing.
